Sharif Tabebordbar

Sharif Tabebordbar is the Co-Founder and Chief Scientific Officer at Kate Therapeutics since October 2021. Previously, Sharif served as a Supervisor and Research Scientist at Broad Institute of MIT and Harvard from June 2017 to October 2021. Their experience also includes roles as a Scientist at Editas Medicine and as a Ph.D. Candidate at Harvard University. Sharif holds a Ph.D. in Biological and Biomedical Sciences from Harvard University, a Master of Science in Molecular Biotechnology from the University of Tehran, and a Bachelor of Science in Biotechnology from the University of Tehran.